Marshall Wace
TCRX icon

Marshall Wace’s TScan Therapeutics TCRX Stock Holding History

Marshall Wace’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240K Sell
237,346
-101,894
-30% -$109K ﹤0.01% 2715
2025
Q4 		$339K Buy
339,240
+292,610
+628% +$424K ﹤0.01% 2403
2025
Q3 		$84.9K Sell
46,630
-7,048
-13% -$12.5K ﹤0.01% 2675
2025
Q2 		$77.8K Buy
+53,678
New +$77.5K ﹤0.01% 2567
2025
Q1 		– Sell
-43,969
Closed -$134K – 3105
2024
Q4 		$134K Sell
43,969
-121,191
-73% -$549K ﹤0.01% 2413
2024
Q3 		$822K Sell
165,160
-142,327
-46% -$859K ﹤0.01% 1728
2024
Q2 		$1.8M Buy
307,487
+116,316
+61% +$916K ﹤0.01% 1428
2024
Q1 		$1.52M Buy
191,171
+80,620
+73% +$507K ﹤0.01% 1486
2023
Q4 		$645K Buy
+110,551
New +$506K ﹤0.01% 1623

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return